物体表面与内部温度存在差异，主要受以下因素影响： 热传导性：不同材料的导热性能不同。金属等良导体，表面与内部温度较为接近；而塑料、木材等不良 导体，表面温度易受环境影响，与内部温度可能存在较大差异。 环境影响：物体表面直接与周围环境（空气温度、气流、阳光照射等）进行热交换，其温度会较快响应 环境变化，而内部温度变化则相对滞后。 要在体表测量核心体温，需要由温度计和热流传感器组成双传感器系统。温度计测量皮肤表面的温度状 况，但由于人体体表温度低于内部温度，皮肤与体内存在温差。这一温差由热流传感器处理，热流传感 器可以测量人体散发的热量。要将皮肤温度和热流的测量值有效转化为核心体温数据，热流传感器必须 具备高灵敏度、低噪声和极低的热漂移特性。 "表面"与"核心"：温度为何存在差异？ 在我们的日常生活与工业应用中，红外测温仪以其非接触、快速、便捷的特点，被广泛运用于人体体温 筛查、设备监测、电动车电池监测、食品加工等众多领域。然而，细心的人们会发现，红外测温仪测量 的总是物体的"表面温度"，而非我们有时更关心的"核心温度"。深圳市佰誉达科技有限公司独家供应的 热流传感器JIRS30正在改变这一现状，凭借热流传感器J ...

Core Viewpoint - The Chinese government will ban the production of mercury thermometers and blood pressure monitors starting January 1, 2026, due to health and environmental concerns related to mercury toxicity [1][4][6]. Industry Impact - Many medical device manufacturers are currently experiencing a supply shortage of mercury thermometers as demand has surged in anticipation of the ban [1][3]. - Companies have been gradually reducing production of mercury thermometers since 2020, preparing for the transition to alternative products [6]. Health Concerns - Mercury is highly toxic and poses significant health risks, particularly to vulnerable populations such as children and pregnant women [4][5]. - The inhalation of mercury vapor can lead to severe health issues, including neurological damage and respiratory problems [4][5]. Alternatives to Mercury Products - The industry is shifting towards non-mercury alternatives, such as electronic thermometers and infrared thermometers, which have become widely accepted and are considered reliable [6][7]. - Recommendations for alternative products include infrared ear thermometers for children and electronic contact thermometers for the elderly, which provide accurate readings and are user-friendly [7].

Core Viewpoint - The production of mercury thermometers and blood pressure monitors will be banned in China starting January 1, 2026, in compliance with the Minamata Convention on Mercury and related regulations [1][2][9]. Regulatory Changes - The National Medical Products Administration (NMPA) has announced that from January 1, 2026, the production of mercury-containing thermometers and blood pressure monitors will be completely prohibited [2][9]. - Existing medical device registration certificates for mercury thermometers and blood pressure monitors will remain valid until their expiration, but renewal applications must be submitted before December 31, 2025 [2][8]. Market Impact - Despite the upcoming ban, mercury thermometers are still available in pharmacies, with prices ranging from 10 to 11 yuan [3][11]. - Sales of mercury thermometers have decreased, and pharmacies are considering replacing them with other temperature measurement tools, such as infrared thermometers [3][11]. Industry Trends - Medical professionals indicate that the withdrawal of mercury thermometers from the market is a natural progression due to safety concerns and the convenience of electronic thermometers [4][12]. - Electronic thermometers and infrared thermometers are becoming more prevalent, with advantages in speed and accuracy compared to mercury thermometers [4][12].

Core Points - Mercury thermometers will be banned from production starting January 1, 2026, as part of China's commitment to the Minamata Convention on Mercury [2][9][13] - The ban includes both mercury thermometers and mercury sphygmomanometers, reflecting a global trend towards safer medical devices [9][14] Group 1: Product Characteristics - Mercury thermometers are known for their high measurement accuracy due to the thermal expansion properties of mercury, making them sensitive to even slight temperature changes [3][8] - The price of mercury thermometers is relatively low, typically around 10 yuan, compared to electronic and infrared thermometers which can cost several tens to hundreds of yuan [5][8] Group 2: Health and Safety Concerns - Despite their accuracy, mercury thermometers pose significant health risks if broken, as mercury is a toxic heavy metal that can lead to acute mercury poisoning [7][8] - A standard mercury thermometer contains approximately 1 gram of mercury, which can significantly increase air mercury concentration if it breaks, posing a danger to health and the environment [7][8] Group 3: Market Trends - There has been a noticeable shortage of mercury thermometers in the market recently, indicating a shift in consumer preference towards electronic and infrared alternatives [5][8] - The transition away from mercury thermometers is seen as a necessary evolution in medical technology, with electronic thermometers offering comparable accuracy and greater convenience [8][9]

Core Viewpoint - The production of mercury thermometers and blood pressure monitors will be banned starting January 1, 2026, as part of China's commitment to the Minamata Convention on Mercury, which aims to reduce mercury pollution and protect public health and the environment [2][12][15]. Group 1: Product Characteristics - Mercury thermometers are known for their high measurement accuracy, being sensitive to even slight temperature changes, and are relatively inexpensive, typically priced around 10 yuan [2][3][10]. - The common mercury thermometer contains approximately 1 gram of mercury, which poses significant health risks if broken, as it can lead to mercury vapor exposure that exceeds safety limits [8][11]. Group 2: Market Trends - There has been a noticeable shortage of mercury thermometers in the market, with prices ranging from a few yuan to around 10 yuan, while alternative electronic and infrared thermometers are significantly more expensive, costing several tens to hundreds of yuan [6][11]. - The transition away from mercury thermometers is driven by their disadvantages, such as being fragile, requiring longer measurement times, and posing health risks due to mercury exposure [11][12]. Group 3: Regulatory Framework - The ban on mercury thermometers is part of the implementation of the Minamata Convention, which came into effect in China on August 16, 2017, and mandates the prohibition of mercury-containing medical devices starting in 2026 [12][15][16]. - The National Medical Products Administration has outlined that existing mercury thermometer products can continue to be registered until December 31, 2025, after which production will cease entirely [15].

Core Points - The power supply is crucial for patient safety in hospitals, and the proactive inspection by the State Grid Dain County Power Supply Company enhances the safety of medical operations [1][3] - The initiative involved a comprehensive safety check of the power system at Dain County People's Hospital, identifying and rectifying three faulty connection points to eliminate potential power outage risks [3][4] - The company distributed over 100 safety electricity handbooks and conducted practical training for medical staff on emergency power switching and electrical fault handling, boosting their confidence in managing power-related emergencies [4] Summary by Sections - **Power Supply Importance**: Stable electricity is essential for the operation of critical medical equipment, such as surgical lights and ICU ventilators, which directly impacts patient health [3] - **Inspection and Rectification**: The inspection led to the identification of five electrical defects, with immediate corrective actions taken to ensure the reliability of the power supply [4] - **Training and Education**: The company provided hands-on training and resources to medical personnel, enhancing their understanding of electrical safety and emergency procedures [4] - **Future Commitment**: The company plans to continue focusing on power safety in key areas like hospitals and schools, reinforcing its commitment to public service and community welfare [4]

Core Viewpoint - The article highlights the dedication and expertise of a power distribution technician, Xia Jun, who has been involved in ensuring reliable power supply during critical examination periods for thirteen years, emphasizing the importance of proactive maintenance and monitoring in the power distribution sector [1][4]. Group 1: Operational Excellence - Xia Jun has participated in 13 years of power supply assurance for examinations, demonstrating a commitment to maintaining the reliability of the power grid [1]. - He has identified 26 equipment defect risks and led the resolution of 18 key issues, including overload and voltage problems, showcasing his proactive approach to operational challenges [2]. - The use of advanced monitoring tools and data analysis allows for precise identification of weak points in the power supply system, enhancing overall reliability [3]. Group 2: Professional Development - Xia Jun progressed from a novice to a senior technician and top skill expert over seven years, reflecting the importance of experience and continuous learning in the industry [3]. - His meticulous planning includes conducting thorough inspections and developing tailored power supply plans for each examination site, ensuring comprehensive preparedness [3]. - The reliability of the power distribution network in his jurisdiction has improved year-on-year under his leadership, indicating effective management and technical expertise [3]. Group 3: Commitment to Service - Xia Jun embodies the spirit of a dedicated technician and a responsible party member, consistently prioritizing the safety and reliability of power supply for students during examinations [4]. - His approach to maintenance is likened to that of a doctor diagnosing and treating equipment issues, emphasizing the critical nature of his role in the power distribution industry [2]. - The article concludes with a reflection on Xia Jun's unwavering commitment to his duties, highlighting the importance of such dedication in ensuring public service reliability [4].

Group 1: R&D Investment and Strategy - The company plans to continue increasing R&D investment, focusing on key product areas and AI strategic layout [1] - A complete R&D pipeline is in place, with budget decisions based on mid-to-long-term strategies [1] - The company has accumulated 26 years of clinical experience, aiming to develop medical-grade wearable devices [2] Group 2: Revenue Growth and Market Expansion - Future growth points include respiratory therapy, blood glucose management, POCT, home health monitoring, and emergency care, with an active expansion into overseas markets [2] - The company achieved a total revenue of CNY 75.66 billion and a net profit of CNY 18.06 billion in 2024 [8] - In Q1 2025, the company reported a revenue of CNY 24.36 billion and a net profit of CNY 6.25 billion [8] Group 3: Competitive Positioning and Market Challenges - The company faces competition from major players like Abbott in the CGM market, with a current market share that is expected to grow [11] - The overseas business has seen a 30% revenue increase, primarily driven by regions like Southeast Asia, Europe, and South America [11] - The company is monitoring the impact of high tariffs in the U.S. on its overseas business and is developing risk management strategies [11] Group 4: Brand and Market Perception - The company emphasizes the importance of brand strength, product quality, and service in enhancing its market position [4] - The company’s goodwill stands at CNY 1.107 billion, accounting for less than 7% of total assets, indicating manageable impairment risks [4] Group 5: Future Outlook and Goals - The company aims to be among the top three in the global home healthcare market, with current contributions from home customers being evaluated [3] - The company is committed to long-term strategies and organic growth, alongside potential acquisitions to drive business expansion [6] - The company acknowledges that its current P/E ratio is undervalued, which may affect market perception [10]

Core Viewpoint - The company is optimistic about its future growth, driven by innovation in product development and strategic partnerships, particularly in the respiratory treatment and health monitoring sectors. Group 1: Financial Performance - In 2024, the company achieved a total revenue of 7.566 billion yuan and a net profit of 1.806 billion yuan. In the first quarter of 2025, revenue was 2.436 billion yuan with a net profit of 625 million yuan [18]. - The company experienced a decline in revenue and net profit in 2023 due to fluctuations in public demand, but expects growth in 2024 compared to 2022 [5][6]. Group 2: Product Development and Market Strategy - The respiratory treatment solutions segment includes oxygen concentrators, ventilators, and nebulizers, with oxygen concentrators holding the largest market share. The company has launched innovative products like the third-generation sleep ventilator and portable oxygen concentrators [1]. - The home health monitoring segment, primarily consisting of electronic blood pressure monitors, has seen a double-digit growth year-on-year in 2024 [1]. - The company is committed to increasing R&D investment to enhance product technology and market competitiveness [2][6]. Group 3: Market Expansion and International Business - The company is actively expanding its overseas market presence, particularly in Southeast Asia, Europe, and South America, with a 30% revenue growth from international sales [5]. - In 2024, overseas revenue accounted for 12.54% of total revenue, with a focus on strengthening local talent and cultural collaboration in these regions [5]. Group 4: Strategic Partnerships and Acquisitions - The partnership with Inogen is aimed at leveraging both companies' resources for long-term strategic collaboration in the respiratory treatment solutions sector [3]. - The company is exploring investment and acquisition opportunities to enhance its business growth and integrate key resources [6][12]. Group 5: Future Goals and Vision - The company aims to achieve over 10 billion yuan in revenue and a market capitalization exceeding 100 billion yuan by 2025, with a long-term vision to be among the top three in the global home healthcare market by 2030 [7][10]. - The company emphasizes the importance of brand strength and customer experience as core components of its growth strategy [36].

Core Viewpoint - The company reported a decline in overall revenue and net profit for 2024, while specific segments like blood glucose management and emergency solutions showed significant growth [1][2]. Financial Performance - In 2024, the company achieved revenue of 7.566 billion yuan, a year-over-year decrease of 5.09%, and a net profit attributable to shareholders of 1.806 billion yuan, down 24.63% year-over-year [1]. - For Q1 2025, the company reported revenue of 2.436 billion yuan, an increase of 9.17% year-over-year, with a net profit of 625 million yuan, down 5.26% year-over-year [1]. Segment Performance - The blood glucose management and POCT solutions segment generated revenue of 1.03 billion yuan in 2024, growing by 40.20% year-over-year, driven by a significant increase in CGM and expansion of BGM customer base [2]. - The emergency solutions segment achieved revenue of 239 million yuan, up 34.05% year-over-year, benefiting from the certification and technological upgrades of the AED products [2]. - The respiratory therapy solutions segment saw revenue decline to 2.597 billion yuan, down 22.42% year-over-year, primarily due to fluctuations in public demand [2]. - The home health monitoring solutions segment reported revenue of 1.564 billion yuan, a slight decrease of 0.41% year-over-year, with some products experiencing growth despite high base effects [2]. - Clinical instruments and rehabilitation solutions generated revenue of 2.093 billion yuan, a marginal increase of 0.24% year-over-year, with certain product categories showing positive trends [2]. Profitability and Cost Management - The company achieved a gross margin of 50.14% in 2024, a decrease of 1.22 percentage points year-over-year, but is expected to stabilize and improve in Q1 2025 to 50.30% [3]. - The sales, management, and financial expense ratios for 2024 were 17.99%, 5.66%, and -3.12%, respectively, with a focus on optimizing costs and resource utilization [3]. International Expansion - The company’s overseas market revenue reached 949 million yuan in 2024, reflecting a year-over-year growth of 30.42%, supported by product registrations and localized team development [3]. Investment Outlook - The company is focused on the home medical device sector, particularly in respiratory and oxygen therapy, blood glucose management, and infection control, with rapid growth in international markets expected to enhance growth potential [4]. - Revenue projections for 2025-2027 are estimated at 8.548 billion yuan, 9.710 billion yuan, and 11.096 billion yuan, with corresponding year-over-year growth rates of 13.0%, 13.6%, and 14.3% [4].